{"id":"NCT00689221","sponsor":"EMD Serono","briefTitle":"Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status","officialTitle":"Cilengitide for Subjects With Newly Diagnosed Glioblastoma and Methylated MGMT Gene Promoter - A Multicenter, Open-label, Controlled Phase III Study, Testing Cilengitide in Combination With Standard Treatment (Temozolomide With Concomitant Radiation Therapy, Followed by Temozolomide Maintenance Therapy) Versus Standard Treatment Alone (CENTRIC)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-09","primaryCompletion":"2012-11","completion":"2013-08","firstPosted":"2008-06-03","resultsPosted":"2014-11-04","lastUpdate":"2014-11-04"},"enrollment":545,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Glioblastoma"],"interventions":[{"type":"DRUG","name":"Cilengitide","otherNames":[]},{"type":"DRUG","name":"Temozolomide","otherNames":[]},{"type":"RADIATION","name":"Radiotherapy","otherNames":[]}],"arms":[{"label":"Cilengitide + Temozolomide + Radiotherapy","type":"EXPERIMENTAL"},{"label":"Temozolomide + Radiotherapy","type":"ACTIVE_COMPARATOR"}],"summary":"CENTRIC is a Phase 3 clinical trial assessing efficacy and safety of the investigational integrin inhibitor, cilengitide, in combination with standard treatment versus standard treatment alone in newly diagnosed glioblastoma subjects with a methylated O6-methylguanine-deoxyribonucleic acid methyltransferase (MGMT) gene promoter in the tumor tissue.\n\nThe MGMT gene promoter is a section of deoxyribonucleic acid (DNA) that acts as a controlling element in the expression of MGMT. Methylation of the MGMT gene promoter has been found to be a predictive marker for benefit from temozolomide (TMZ) treatment.","primaryOutcome":{"measure":"Overall Survival (OS) Time","timeFrame":"Time from randomization to death or last day known to be alive, reported between day of first participant randomized, that is, Sep 2008 until cut-off date, (19 Nov 2012)","effectByArm":[{"arm":"Cilengitide + Temozolomide + Radiotherapy","deltaMin":26.3,"sd":null},{"arm":"Temozolomide + Radiotherapy","deltaMin":26.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.8623"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":2,"countries":["United States","Germany"]},"refs":{"pmids":["36346112","25163906"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":138,"n":263},"commonTop":["NAUSEA","HEADACHE","FATIGUE","CONSTIPATION","VOMITING"]}}